TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07138846: A Randomized, Double-blind, Multi-center, Phase III Study of MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

Sponsor: Lepu Biopharma Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 231 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07138846 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07138846 Rescue Dossier →